Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. alleging securities fraud that negatively impacted investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the defendants overstated the demand for RxSight's products, which resulted in the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [2]. - The positive statements made by the defendants regarding the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Investor Information - Investors who suffered losses during the relevant time frame have until September 22, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors, leading to a significant stock price decline [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, resulting in a 38% drop in stock price from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization, caused another 38% decline in stock price from $12.79 to $7.95 per share [6].

Company Overview - RxSight, Inc. is an ophthalmic medical device company focused on providing high-quality customized vision for patients after cataract surgery [3] - The company offers the RxSight Light Adjustable Lens system, which includes the RxSight Light Adjustable Lens (LAL/LAL+), Light Delivery Device (LDD™), and accessories, representing the first and only commercially available intraocular lens technology that can be adjusted post-surgery [3] Upcoming Events - RxSight's management is scheduled to present at the Wells Fargo Healthcare Conference in Boston on September 4, 2025, at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time [2] - A live and archived webcast of the presentation will be available on the company's investor relations website [2]

NEW YORK, Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of RxSight, Inc. (NASDAQ: RXST). Shareholders who purchased shares of RXST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/rxsight-inc-loss-submission-form/?id=161238&from=4 SOURCE The Gross Law Firm ALLEGATIONS ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of RxSight, Inc. about a class action lawsuit due to alleged misleading statements and failure to disclose critical issues affecting the company's performance [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from November 7, 2024, to July 8, 2025 [3]. - Allegations include that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [3]. - It is claimed that the company overstated the demand for its products and was unlikely to meet its financial guidance for fiscal year 2025 [3]. - The positive statements made by the defendants regarding the company's business and prospects are alleged to be materially misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 22, 2025, to participate in potential recovery [4]. - Upon registration, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors during the relevant period [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of misleading statements and failure to disclose significant operational challenges that have negatively impacted the company's financial performance [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against RxSight [4]. - Investors who suffered losses in RxSight between November 7, 2024, and July 8, 2025, are encouraged to contact the firm to discuss their legal rights [1][9]. Group 2: Allegations Against RxSight - The complaint alleges that RxSight and its executives violated federal securities laws by making false or misleading statements regarding the company's sales and product demand [6]. - Specific allegations include that the company faced "adoption challenges" leading to declines in sales and utilization, overstated demand for its products, and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [6]. Group 3: Financial Performance and Market Reaction - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, showing significant declines in LDD sales, LAL utilization, and overall revenue, along with a lowered full-year guidance by approximately $42.5 million at the midpoint [7]. - Following this announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, amid unusually heavy trading volume [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified class period of their potential entitlement to compensation through a class action lawsuit [1][4]. Group 1: Class Action Details - The class period for the lawsuit is from November 7, 2024, to July 8, 2025, and the lead plaintiff deadline is September 22, 2025 [1][2]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2][6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation [3]. Group 3: Allegations Against RxSight - The lawsuit alleges that RxSight made false and misleading statements regarding its sales and utilization, overstated product demand, and was unlikely to meet its financial guidance for fiscal year 2025 [4]. - The claims suggest that the positive statements made by RxSight about its business and prospects were materially misleading and lacked a reasonable basis [4].

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rxsight-inc-lawsuit- ...

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material informat ...